Developer

Tetra Discovery Partners

1compound
2programs
2indications
Phase 3lead asset

Phase distribution

  • Phase 31
  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • May 2020AcquisitionShionogi acquires Tetra Therapeutics, taking ownership of zatolmilast (BPN14770)Shionogi acquired Tetra Therapeutics (formerly Tetra Discovery Partners, Grand Rapids, Michigan) in May 2020, having first collaborated on the program from December 2018; Tetra became a wholly-owned Shionogi Group company and remains the registered sponsor of the zatolmilast trials. The acquisition was disclosed alongside the PICASSO AD Phase 2 primary-endpoint miss.Zatolmilastsource ↗

Catalysts · 1 upcoming · 3 reported

  • 2H 2026Anticipated

    ZatolmilastforFragile X syndromeFull results

    Program-decision update on zatolmilast in fragile X syndrome: Shionogi plans to analyze the EXPERIENCE-302 open-label extension alongside exploratory analyses of EXPERIENCE-301/-204, engage the FDA, and update the FXS community in the second half of 2026 — effectively the program's go/no-go catalyst.

    NCT05367960source ↗

Recently reported

  • 2026-05-13missed

    ZatolmilastforFragile X syndromeTopline data

    EXPERIENCE-301 (adult) missed its primary endpoint: zatolmilast did not improve the NIH Toolbox Crystallized Cognition Composite vs placebo at Week 13 in adult males with fragile X syndrome, though significant caregiver-rated FXS-NRS language/communication and daily-function differences were observed ('suggestive of an efficacy signal', not conclusive).

    source ↗

  • 2026-05-13missed

    ZatolmilastforFragile X syndromeTopline data

    EXPERIENCE-204 (adolescent) missed its primary endpoints (FXS-NRS language/communication and daily function) and its key secondary (CGI-I of Language) in male adolescents with fragile X syndrome; generally well tolerated, no new safety concerns.

    source ↗

  • 2020-05-31missed

    ZatolmilastforAlzheimer's diseaseTopline data

    PICASSO AD Phase 2 missed its primary endpoint: BPN14770 did not separate from placebo on the RBANS Delayed Memory Index at Week 13 in 255 patients with early Alzheimer's disease (~+10 points in all arms); disclosed alongside Shionogi's acquisition of Tetra in May 2020.

    source ↗

Recent activity

  • May 13, 2026ReadoutZatolmilast·Fragile X syndromemissedEXPERIENCE-301 (adult) missed its primary endpoint: zatolmilast did not improve the NIH Toolbox Crystallized Cognition Composite vs placebo at Week 13 in adult males with fragile X syndrome, though significant caregiver-rated FXS-NRS language/communication and daily-function differences were observed ('suggestive of an efficacy signal', not conclusive).source ↗
  • May 13, 2026ReadoutZatolmilast·Fragile X syndromemissedEXPERIENCE-204 (adolescent) missed its primary endpoints (FXS-NRS language/communication and daily function) and its key secondary (CGI-I of Language) in male adolescents with fragile X syndrome; generally well tolerated, no new safety concerns.source ↗
  • Sep 27, 2023Phase changeZatolmilast·Alzheimer's diseasePhase 2Program dormant: by the date of Shionogi's Rare Pediatric Disease Designation press release — which describes the zatolmilast clinical program as the fragile X EXPERIENCE studies plus a preclinical PDE4B asset, with no mention of Alzheimer's disease — the AD indication had been absent from sponsor communications for over three years and no new AD trial had been registered. No formal discontinuation statement is citable, so the status token is 'unknown' rather than 'discontinued'; a sponsor statement either way is the re-trigger to update this row.source ↗
  • Nov 1, 2022Phase changeZatolmilast·Fragile X syndromePhase 3Phase 3 EXPERIENCE-301 (NCT05358886) started: randomized, double-blind, placebo-controlled study of zatolmilast 25 mg BID in male adults aged 18–45 with FXS (final enrollment 171). The EXPERIENCE-302 open-label extension (NCT05367960) started the same day. Protocol amendments announced 2024-07-18 widened access (minimum age lowered to 9, weight floor lowered to 55 lb, remote visits, OLE extended to two years).source ↗
  • Mar 29, 2022Phase changeZatolmilast·Fragile X syndromePhase 2/3Pivotal EXPERIENCE program opened with EXPERIENCE-204 (NCT05163808), a randomized, double-blind, placebo-controlled two-part Phase 2/3 study in male adolescents aged 9–17 (zatolmilast 15 or 25 mg BID vs placebo; final enrollment 163).source ↗
  • May 31, 2020ReadoutZatolmilast·Alzheimer's diseasemissedPICASSO AD Phase 2 missed its primary endpoint: BPN14770 did not separate from placebo on the RBANS Delayed Memory Index at Week 13 in 255 patients with early Alzheimer's disease (~+10 points in all arms); disclosed alongside Shionogi's acquisition of Tetra in May 2020.source ↗
  • Feb 4, 2020Phase changeZatolmilast·Alzheimer's diseasePhase 2PICASSO AD reached primary completion. The primary endpoint (RBANS Delayed Memory Index change at Week 13) was missed — all three arms improved by ~10 points (10.1 / 9.9 / 9.7 for 10 mg / 25 mg / placebo per the posted results) — disclosed in May 2020 alongside the announcement of Shionogi's acquisition of Tetra. No safety issues were observed. A CDR-SB subgroup signal in the 25 mg arm was described at the time as warranting further development, but no further Alzheimer's study was ever registered.source ↗
  • Apr 30, 2019Phase changeZatolmilast·Alzheimer's diseasePhase 2PICASSO AD (NCT03817684) started: randomized, double-blind, placebo-controlled 3-arm Phase 2 study of BPN14770 10 mg and 25 mg BID vs placebo for 13 weeks in 255 patients with early Alzheimer's disease, run by Tetra Discovery Partners at ~60 US sites, under the December 2018 development collaboration with Shionogi.source ↗
  • Jul 9, 2018Phase changeZatolmilast·Fragile X syndromePhase 2Phase 2 randomized, double-blind, placebo-controlled two-period crossover study of BPN14770 25 mg BID in 30 adult males with fragile X syndrome started (NCT03569631, Tetra Discovery Partners; completed 2020-07-31). Published as Berry-Kravis et al., Nat Med 2021: primary endpoint was safety; exploratory efficacy showed cognitive improvement in language domains (picture vocabulary, oral reading recognition) and clinically meaningful daily-function gains.source ↗

Competitive landscape

Other companies developing against Tetra Discovery Partners's targets or indications.